Non-invasive monitoring of liver fibrosis

British Medical Bulletin

Volumn 112, Issue 1, 2014, Pages 97-106

  Scott, Robert ^a   Guha, Indra Neil ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

biomarkers; cirrhosis; fibrosis; imaging; review

Indexed keywords

2 [2,6 DIMETHYL 4 [3 [4 (METHYLTHIO)PHENYL] 3 OXO 1 PROPENYL]PHENOXY] 2 METHYLPROPIONIC ACID; ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ANTIVIRUS AGENT; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; MRI SCANER; PLACEBO; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ALGORITHM; BARD SCORE; BARIATRIC SURGERY; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG SAFETY; ELASTOGRAPH; ELASTOGRAPHY; GOLD STANDARD; HEPASCORE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER FUNCTION TEST KIT; MAGNETIC RESONANCE ELASTOGRAPHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MONITORING; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOMES RESEARCH; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SCREENING TEST; SERUM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VIRUS HEPATITIS; BIOPSY; BLOOD; LIVER; MEDICAL RESEARCH; PATHOLOGY; PROCEDURES; TRENDS;

BIOMARKERS; BIOMEDICAL RESEARCH; BIOPSY; DISEASE PROGRESSION; HUMANS; LIVER; LIVER CIRRHOSIS;

EID: 84925292409     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldu031     Document Type: Review

References (51)

1. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003; 38(Suppl. 1): S38-53
2. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
3. Fleming KM, Aithal GP, Solaymani-Dodaran M, et al. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. J Hepatol 2008; 49: 732-8
4. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: 195-99
5. Donnan PT, McLernon D, Dillon JF, et al. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technol Assess 2009; 13: 1-134
6. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-Alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56: 234-40
7. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81
8. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57
9. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20
10. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75
11. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13
12. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73
13. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62
14. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-21
15. Chen J, Talwalkar JA, Yin M, et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56
16. Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 2014; 60: 69-77
17. Steadman R, Myers RP, Leggett L, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol 2013; 27: 149-58
18. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis (ELF) assay. Hepatology 2008; 48: 1549-57
19. Naveau S, Gaude G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105
20. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51
21. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9
22. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-61
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93
24. Roulot D, Costes JL, Buyck JF, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60: 977-84
25. Wong VWS, Chu WCW, Wong GLH, et al. Prevalence of non-Alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-15
26. Harman DJ, Wilkes EA, James MW, et al. Non-invasive biomarkers unearth undiagnosed cirrhosis in the community. Hepatology 2013; 58: 328-9
27. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50
28. Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and FibroScan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507-15
29. Crespo G, Fernández-Varo G, Mariño Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol 2012; 57: 281-7
30. Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-7
31. Boursier J, de Ledinghen V, Zarski JP, et al.comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology 2012; 55: 58-67
32. Poynard T, Munteanu M, Deckmyn O, et al. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol 2012; 57: 541-8
33. Fontana RJ, Dienstag JL, Bonkovsky HL, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010; 59: 1401-9
34. Forestier N, Gaus A, Herrmann E, et al. Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. J Gastrointestin Liver Dis 2012; 21: 367-73
35. Poynard T, Munteanu M, Colombo M, et al. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program. J Hepatol 2011; 54: 227-35
36. Martinez SM, Fernandez-Varo G, Gonzalez P, et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-48
37. Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-Analysis. J Viral Hepat 2011; 19: 212-9
38. Hoad CL, Palaniyappan N, Kaye P, et al. Quantitative magnetic resonance imaging (MRI) in the evaluation of the degree of steatosis, iron accumulation and fibrosis in chronic liver disease (MRker study). J Hepatol 2013; 58 (S1): S285-6
39. Bavu E, Gennisson JL, Couade M, et al. Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. Ultrasound Med Biol 2011; 37: 1361-73
40. Forestier J, Dumortier J, Guillaud O, et al. Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests. Eur J Gastroenterol Hepatol 2010; 22: 532-40
41. Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol 2009; 193: 14-27
42. Wang QB, Zhu H, Liu HL, et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a metaanalysis. Hepatology 2012; 56: 239-47
43. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18
44. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50
45. Lotersztajn S, Julien B, Teixeira-Clerc F, et al. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2004; 45: 605-28
46. Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-Associated cytokines. Hepatology 1996; 24: 759-65
47. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61
48. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-406
49. Nalpas B, Lavialle-Meziani R, Plancoulaine S, et al. Interferon g receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection. Gut 2010; 59: 1120-6
50. Hemmann S, Graf J, Roderfeld M, et al. Expression of MMPs and TIMPs in liver fibrosis-A systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46: 955-75
51. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46: 297-306